David Beauvais

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Emmanuel Bachy, Steven Le Gouill, Roberta Di Blasi et al. · Nature Medicine · 2022 · 383 citations · Full text

Medicine, Hematology, Oncology +15

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi, Steven Le Gouill, Emmanuel Bachy et al. · Blood · 2022 · 148 citations · Full text

Medicine, Immunology, Oncology +16

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

Élie Azoulay, Pedro Castro, Adel Maamar et al. · The Lancet Haematology · 2021 · 99 citations · Full text

Life Sciences, Immunology, Internal Medicine +13

Monitoring <scp>CAR</scp> T‐cells using flow cytometry

Julie Demaret, Pauline Varlet, Jacques Trauet et al. · Cytometry Part B Clinical Cytometry · 2020 · 81 citations · Full text

Medicine, Hematology, Immunology +17

Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

Jean Lemoine, Emmanuel Bachy, Guillaume Cartron et al. · Blood Advances · 2023 · 77 citations · Full text

Medicine, Immunology, Oncology +13